forumAdmin
20-11-2007, 07:59 PM
Sciele Pharma, Inc. (NASDAQ:SCRX), a specialty pharmaceutical company, and Addrenex Pharmaceuticals, today announced the initiation of patient enrollment for Phase III clinical trials in the U.S. for Clonicel to treat attention deficit and hyperactivity disorder (ADHD) in children. In July 2007, Sciele signed an exclusive licensing agreement with Addrenex to market a sustained-release formulation of clonidine hydrochloride for the treatment of ADHD and hypertension. [click link for full article]
External site More Info... (http://www.medicalnewstoday.com/articles/87455.php)
External site More Info... (http://www.medicalnewstoday.com/articles/87455.php)